Publicado 6 números por año
ISSN Imprimir: 1045-4403
ISSN En Línea: 2162-6502
Indexed in
Parathyroid Hormone-Related Protein in Prostate Cancer
SINOPSIS
Although originally discovered as the peptide responsible for humoral hypercalcemia of malignancy (HHM), parathyroid hormone-related protein (PTHrP) has been shown to play a major role in fetal development. In the adult, it is widely distributed in normal and various cancer tissues. In spite of the rarity of HHM in prostate cancer, PTHrP is widely distributed in prostate cancer cells. PTHrP is a precursor molecule with generation of various fragments with distinct biological activities. More recent studies have shown that there is intranuclear localization of PTHrP and that intracrine effects of the peptide are involved in promoting processes that result in tumor progression (cell proliferation, apoptosis, cell attachment and angiogenesis) in prostate cancer. PTHrP expression is controlled by three distinct promoters, with P3 being used most often in cancer cells. The factors that control PTHrP production via interaction with the promoters are growth factors, androgens, vitamin D analogs, and adenoviral proteins. TGF-β and its effector Smad3 activate the P3 promoter through an AGAC box and an Ets binding site involving Ets1 and to some extent Ets2 proteins. In addition, TGF-β stimulates P3 promoter activity via Smad-independent pathways that involve the p38 MAP kinase. Although the addition of PTHrP or transfection with the PTHrP gene in prostate cells results in effects that promote tumor development, studies that employ inhibition of PTHrP activity in vitro and in vivo are needed to establish a definitive role of this peptide in the pathogenesis of prostate cancer.
-
Asadi Farrokh K., Kukreja Subhash C., Boyer Brigitte, Valess Ana-Maria, Cook James L., E1A oncogene expression inhibits PTHrP P3 promoter activity and sensitizes human prostate cancer cells to TNF-induced apoptosis, International Urology and Nephrology, 42, 4, 2010. Crossref
-
Maass Philipp G., Wirth Jutta, Aydin Atakan, Rump Andreas, Stricker Sigmar, Tinschert Sigrid, Otero Miguel, Tsuchimochi Kaneyuki, Goldring Mary B., Luft Friedrich C., Bähring Sylvia, A cis-regulatory site downregulates PTHLH in translocation t(8;12)(q13;p11.2) and leads to Brachydactyly Type E, Human Molecular Genetics, 19, 5, 2010. Crossref
-
Shukeir Nicholas, Garde Seema, Wu Jinzi J., Panchal Chandra, Rabbani Shafaat A., Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer, Anti-Cancer Drugs, 16, 10, 2005. Crossref
-
Alonso V., Pérez-Martínez F.C., Calahorra F.J., Esbrit P., Phytoestrogen modulation of bone-related cytokines and its impact on cell viability in human prostate cancer cells, Life Sciences, 85, 11-12, 2009. Crossref
-
Agirregoitia Naiara, Casis Luis, Gil Javier, Ruiz Fátima, Irazusta Jon, Ontogeny of prolyl endopeptidase and pyroglutamyl peptidase I in rat tissues, Regulatory Peptides, 139, 1-3, 2007. Crossref
-
Antoniou Antonis C, Kuchenbaecker Karoline B, Soucy Penny, Beesley Jonathan, Chen Xiaoqing, McGuffog Lesley, Lee Andrew, Barrowdale Daniel, Healey Sue, Sinilnikova Olga M, Caligo Maria A, Loman Niklas, Harbst Katja, Lindblom Annika, Arver Brita, Rosenquist Richard, Karlsson Per, Nathanson Kate, Domchek Susan, Rebbeck Tim, Jakubowska Anna, Lubinski Jan, Jaworska Katarzyna, Durda Katarzyna, Złowowcka-Perłowska Elżbieta, Osorio Ana, Durán Mercedes, Andrés Raquel, Benítez Javier, Hamann Ute, Hogervorst Frans B, van Os Theo A, Verhoef Senno, Meijers-Heijboer Hanne EJ, Wijnen Juul, Gómez Garcia Encarna B, Ligtenberg Marjolijn J, Kriege Mieke, Collée J Margriet, Ausems Margreet GEM, Oosterwijk Jan C, Peock Susan, Frost Debra, Ellis Steve D, Platte Radka, Fineberg Elena, Evans D Gareth, Lalloo Fiona, Jacobs Chris, Eeles Ros, Adlard Julian, Davidson Rosemarie, Cole Trevor, Cook Jackie, Paterson Joan, Douglas Fiona, Brewer Carole, Hodgson Shirley, Morrison Patrick J, Walker Lisa, Rogers Mark T, Donaldson Alan, Dorkins Huw, Godwin Andrew K, Bove Betsy, Stoppa-Lyonnet Dominique, Houdayer Claude, Buecher Bruno, de Pauw Antoine, Mazoyer Sylvie, Calender Alain, Léoné Mélanie, Bressac- de Paillerets Brigitte, Caron Olivier, Sobol Hagay, Frenay Marc, Prieur Fabienne, Ferrer Sandra Fert, Mortemousque Isabelle, Buys Saundra, Daly Mary, Miron Alexander, Terry Mary Beth, Hopper John L, John Esther M, Southey Melissa, Goldgar David, Singer Christian F, Fink-Retter Anneliese, Tea Muy-Kheng, Kaulich Daphne Geschwantler, Hansen Thomas VO, Nielsen Finn C, Barkardottir Rosa B, Gaudet Mia, Kirchhoff Tomas, Joseph Vijai, Dutra-Clarke Ana, Offit Kenneth, Piedmonte Marion, Kirk Judy, Cohn David, Hurteau Jean, Byron John, Fiorica James, Toland Amanda E, Montagna Marco, Oliani Cristina, Imyanitov Evgeny, Isaacs Claudine, Tihomirova Laima, Blanco Ignacio, Lazaro Conxi, Teulé Alex, Valle J Del, Gayther Simon A, Odunsi Kunle, Gross Jenny, Karlan Beth Y, Olah Edith, Teo Soo-Hwang, Ganz Patricia A, Beattie Mary S, Dorfling Cecelia M, van Rensburg Elizabeth Jansen, Diez Orland, Kwong Ava, Schmutzler Rita K, Wappenschmidt Barbara, Engel Christoph, Meindl Alfons, Ditsch Nina, Arnold Norbert, Heidemann Simone, Niederacher Dieter, Preisler-Adams Sabine, Gadzicki Dorothea, Varon-Mateeva Raymonda, Deissler Helmut, Gehrig Andrea, Sutter Christian, Kast Karin, Fiebig Britta, Schäfer Dieter, Caldes Trinidad, de la Hoya Miguel, Nevanlinna Heli, Muranen Taru A, Lespérance Bernard, Spurdle Amanda B, Neuhausen Susan L, Ding Yuan C, Wang Xianshu, Fredericksen Zachary, Pankratz Vernon S, Lindor Noralane M, Peterlongo Paolo, Manoukian Siranoush, Peissel Bernard, Zaffaroni Daniela, Bonanni Bernardo, Bernard Loris, Dolcetti Riccardo, Papi Laura, Ottini Laura, Radice Paolo, Greene Mark H, Loud Jennifer T, Andrulis Irene L, Ozcelik Hilmi, Mulligan Anna Marie, Glendon Gord, Thomassen Mads, Gerdes Anne-Marie, Jensen Uffe B, Skytte Anne-Bine, Kruse Torben A, Chenevix-Trench Georgia, Couch Fergus J, Simard Jacques, Easton Douglas F, Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers, Breast Cancer Research, 14, 1, 2012. Crossref
-
Seeman Ego, Strewler Gordon J, Clinical and basic research papers – April 2005 selections, BoneKEy-Osteovision, 2, 5, 2005. Crossref
-
Smith A.M., Findlay V.J., Bandurraga S.G., Kistner-Griffin E., Spruill L.S., Liu A., Golshayan A.R., Turner D.P., ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype, Carcinogenesis, 33, 3, 2012. Crossref
-
Susa Takao, Ikaga Reina, Kajitani Takashi, Iizuka Masayoshi, Okinaga Hiroko, Tamamori‐Adachi Mimi, Okazaki Tomoki, Wild‐type and specific mutant androgen receptor mediates transcription via 17β‐estradiol in sex hormone‐sensitive cancer cells, Journal of Cellular Physiology, 230, 7, 2015. Crossref
-
McCarty Mark F., Block Keith I., Toward a Core Nutraceutical Program for Cancer Management, Integrative Cancer Therapies, 5, 2, 2006. Crossref
-
Furesi Giulia, Rauner Martina, Hofbauer Lorenz C., Emerging Players in Prostate Cancer–Bone Niche Communication, Trends in Cancer, 7, 2, 2021. Crossref
-
Yoshida Go J., Saya Hideyuki, Molecular pathology underlying the robustness of cancer stem cells, Regenerative Therapy, 17, 2021. Crossref
-
Schwartz Gary G., Prostate Cancer, Serum Parathyroid Hormone, and the Progression of Skeletal Metastases, Cancer Epidemiology, Biomarkers & Prevention, 17, 3, 2008. Crossref